In-person Focus Groups in the Management of Urinary Incontinence in Women

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT05395793
Collaborator
(none)
10
1
5.9
1.7

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate how a support group with other individuals who share the condition urinary incontinence (UI) impacts patients experience with management of urinary incontinence.

Condition or Disease Intervention/Treatment Phase
  • Other: Support Group

Detailed Description

Focus groups in various settings have demonstrated the ability to alleviate psychological and physiological distress in focus group participants. The exploration of focus groups is warranted to measure the potential benefit for patients with urinary incontinence. Researchers aimed to assess the feasibility and acceptability of in-person focus groups as a potential intervention for female patients with urinary incontinence from a mixed methods approach. A mixed methods pilot study will be conducted to investigate whether in-person focus group demonstrate meaningful significance in quantitative outcomes measured by validated questionnaires and qualitative outcomes analyzed from focus group transcripts and post-session surveys. This study was an initial assessment to determine whether in-person focus groups for females with UI is strong enough to warrant further research and clinical implementation.

Study Design

Study Type:
Observational
Actual Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Role of In-person Focus Groups in the Management of Urinary Incontinence in Women From a Mixed-methods, Randomized Pilot Study
Actual Study Start Date :
Apr 1, 2019
Actual Primary Completion Date :
Sep 29, 2019
Actual Study Completion Date :
Sep 29, 2019

Outcome Measures

Primary Outcome Measures

  1. Change in mixed urinary incontinence symptoms [Baseline, 12 weeks]

    Measured using the Medical, Epidemiological, and Social Aspects of Aging (MESA) incontinence questionnaire which consists 15 questions to measure urgency of urinary incontinence and stress urinary incontinence on a 0-3 scale (0=Never, 3=Often). Higher total scores indicating higher severity of urge and stress incontinence.

  2. Change in urinary distress [Baseline, 12 weeks]

    Measured using the Urogential Distress Inventory-6 (UDI-6) questionnaire which consists of 6 questions that rate urinary distress experience and how much it subjects are bothered by them on a 0-3 scale (0=not at all; 3=greatly).

  3. Change in overactive bladder satisfaction with treatment [Baseline, 12 weeks]

    Measured using the Overactive Bladder Satisfaction with Treatment Questionnaire (OAB-SAT-q) which consists of 11 questions rating satisfaction or dissatisfaction with treatment for overactive bladder.

  4. Change in urinary tract condition severity [Baseline, 12 weeks]

    Measured using the Patient Global Impression of Severity (PGI-S) questionnaire which consists of one question that asks subject to describe urinary tract condition currently on a scale of 1=normal, 2=mild, 3=moderate, 4=severe.

  5. Change in urinary tract condition improvement [Baseline, 12 weeks]

    Measured using the Patient Global Impression of Improvement (PGI-I) questionnaire which consists of one question that asks subject to rate urinary tract condition currently, compared with how it was before taking medication on a scale of 1-7 (1=very much better; 7=very much worse)

  6. Change in sexual quality of life [Baseline, 12 weeks]

    Measured using the Sexual Quality of Life Questionnaire- Female (SQoL-F) which consists of 18 questions to assess the relationship of sexual dysfunction and quality of life on a scale of 1-6 (1=completely agree; 6=completely disagree. Higher total scores indicate greater quality of life.

  7. Change in Patient Health Questionnaire [Baseline, 12 weeks]

    Measured using the Patient Health Questionnaire (PHQ-9) which consists of 9 questions to assess depressive symptoms using a scale of 0-3 (0=not at all; 3=nearly every day). Higher total scores indicate greater severity depression.

  8. Change in physical activity [Baseline, 12 weeks]

    Measured using the International Physical Activity Questionnaire (IPAQ) to assess physical activity as part of everyday life.

Secondary Outcome Measures

  1. Measure feasibility and acceptability of focus group [Baseline, 2 weeks, 4 weeks]

    written survey was administered at the beginning of each focus group session which incorporated open-ended warm-up questions regarding urinary incontinence and concluded with the assessment of the level of focus group comfort on a scale from 1-5

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years or older

  • English-speaking

  • Have the ability to commute to the meeting facility without institutional assistance

Exclusion Criteria:

• Those unable to attend all three focus group sessions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Arizona Scottsdale Arizona United States 85259

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Aqsa Khan, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Aqsa A. Khan, MD, Assistant Professor Department of Urology, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT05395793
Other Study ID Numbers:
  • 18-009815
First Posted:
May 27, 2022
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022